Clinical trials recruiting for Advanced Breast Cancer
61
Recruiting trials
41
US states with sites
40
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Fulvestrant | 10 |
| Bevacizumab | 3 |
| Elacestrant | 3 |
| Everolimus | 3 |
| Pyrotinib | 3 |
| Ribociclib | 3 |
| SHR-A1811 | 3 |
| SHR-A1921 | 3 |
| SHR-A2102 | 3 |
| TPC | 3 |
| Abemaciclib | 2 |
| Apatinib | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 10 |
| California | 8 |
| Florida | 8 |
| Massachusetts | 8 |
| New York | 8 |
| Michigan | 7 |
| Missouri | 7 |
| Tennessee | 6 |
| Colorado | 5 |
| Virginia | 5 |
| Arizona | 4 |
| Illinois | 4 |
Top cities
Houston, Texas 9Boston, Massachusetts 8New York, New York 8San Antonio, Texas 7St Louis, Missouri 7Nashville, Tennessee 6Fairfax, Virginia 4Indianapolis, Indiana 4Los Angeles, California 4Chicago, Illinois 3
Self-screener
Recruiting trials
- A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
- A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
- A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
- A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
- A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
- Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
- Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
- Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
- Dalpiciclib in HR+/HER2- ABC
- Decision Support Tool for Patients With Advanced Breast Cancer
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
- Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Engage Psychosocial Intervention for Cancer Symptoms
- Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
- Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
- Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
- FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
- Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
- RC48-ADC in HER2-low Advanced Breast Cancer
- Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
- SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Southeast Netherlands Advanced Metastatic Breast Cancer Registry
- Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
- Study of DM5167 in Patients With Advanced Solid Tumors
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
- Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
- The COMPASSION Study
- The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
- Timing of ctDNA Testing in Advanced Breast Cancer
- Trastuzumab Deruxtecan in Advanced Breast Cancer
- Whole Body MRI in Oncology
Related conditions
Trials recruiting for Advanced Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Metastatic breast cancer 131HER2- Negative Breast Cancer 57Lung cancer 2180Colorectal cancer 1359Hormone Receptor Positive Tumor 10Prostate cancer 1234PIK3CA Mutation 3Hormone Receptor-positive Breast Cancer 24Advanced Prostate Cancer 13
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Advanced Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.